Investigational drug · Phase 3
ABP 692
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsing-remitting Multiple Sclerosis (RRMS).
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ABP 692"
First trial start
2025
Jan 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABP 692", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsing-remitting Multiple Sclerosis (RRMS)
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABP 692" as an intervention, largest first.
- Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Pivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06700343 · 152 participants · Start Jan 13, 2025 · Primary completion Apr 19, 2027
Drug: Ocrelizumab (US); Ocrelizumab (EU) and 1 more · For: Relapsing-remitting Multiple Sclerosis (RRMS)
Sites: Mobile, Alabama; Scottsdale, Arizona; Carlsbad, California · 109 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsing-remitting Multiple Sclerosis (RRMS)
- RocbrutinibLP-168, NWP-775Phase 36 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma
- IMU-838Vidofludimus calciumPhase 33 trials
Immunic AG · Relapsing-Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- BCD-281Phase 31 trial
Biocad · Relapsing-remitting Multiple Sclerosis (RRMS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.